RecruitingPhase 2NCT06532279
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Studying Nasopharyngeal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NRG Oncology
- Principal Investigator
- David M Brizel, M.DNRG Oncology
- Intervention
- Best Practice(other)
- Enrollment
- 98 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (30)
- Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
- Arizona Center for Cancer Care-Peoria, Peoria, Arizona, United States
- Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
- Arizona Center for Cancer Care - Scottsdale, Scottsdale, Arizona, United States
- Arizona Center for Cancer Care-Surprise, Surprise, Arizona, United States
- Arizona Center for Cancer Care, Tempe, Arizona, United States
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States
- Keck Medicine of USC Buena Park, Buena Park, California, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- Los Angeles General Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
- Shaw Cancer Center, Edwards, Colorado, United States
- George Washington University Medical Center, Washington D.C., District of Columbia, United States
- Sarasota Memorial Hospital-Venice, N. Venice, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06532279 on ClinicalTrials.govOther trials for Nasopharyngeal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06980038Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07362979Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaSun Yat-sen University
- RECRUITINGNANCT06796270Hypofractionated Radiotherapy for Nasopharyngeal CarcinomaThe Second Affiliated Hospital of Hainan Medical University
- RECRUITINGPHASE2NCT06059261Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.Chongqing University Cancer Hospital
- RECRUITINGNCT07376603IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk FeaturesQiaojuan Guo
- RECRUITINGPHASE3NCT07340515Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III TrialMan Hu
- RECRUITINGPHASE3NCT0732885440.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaMing-Yuan Chen
- RECRUITINGNCT07232680Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon ChemoradiotherapyCheng-En Hsieh